

## Ana Marli Christovam Sartori

Ana Marli Christovam Sartori, MD, PhD, Associate Professor at the Department of Infectious and Parasitic Diseases of the Medical School of Sao Paulo University and clinician at the Reference Center for Specials Immunobiologicals (CRIE) of the Hospital das Clínicas, a tertiary/quaternary hospital attached to the same university, in Sao Paulo, Brazil.

Area of interest – Evaluation of vaccines and vaccination programs, including economic evaluation of vaccination programs.

---

## Anna Durbin

I am currently Professor of International Health at the Johns Hopkins Bloomberg School of Public Health (JHSPH). I have been faculty at the JHSPH since 1999. Prior to attaining this faculty position, I spent 5 years in the Laboratory of Infectious Diseases, NIAID, NIH using recombinant DNA technology to develop live attenuated respiratory virus vaccines. I am a board-certified physician (Internal Medicine and Infectious Diseases) who has extensive experience in the conduct of early phase clinical trials. My research interest involves the human responses to live attenuated vaccines and subunit protein vaccines, with a primary focus on the flavivirus vaccines, particularly those for dengue and Zika virus. My group has developed two dengue controlled human infection models (D-CHIM) to down-select candidate vaccines and characterize the human immune response to dengue viruses. We have utilized our clinical vaccine studies and the D-CHIM to characterize the human clinical and immune responses to natural dengue infection and to live attenuated dengue vaccines. By fully characterizing the cellular and humoral immune response to the vaccines we administered to healthy volunteers, we hope to identify correlates of immunity to the target pathogens as well optimize the formulation of different vaccines. I have acted as the Principal Investigator for 30 clinical trials of live attenuated candidate dengue vaccines. Through these trials, we have identified the candidate live attenuated tetravalent dengue vaccine with the most favorable safety, infectivity, and immunogenicity profiles and have initiated trials of this candidate in dengue endemic areas. I have also been very involved in teaching at the Bloomberg School of Public Health. I have taught the Biological Basis of Vaccine Development since 2002 and have coordinated the Vaccine Science and Policy Certificate Program since 2006. I have advised approximately 35 MPH and MHS students and four PhD students during my tenure. Two of my PhD advisees have graduated. One is faculty at the University of Pittsburgh School of Public Health and another worked with the dengue program at the World Health Organization prior to becoming a CDC EIS officer. I am currently working to develop and evaluate a live attenuated Zika virus vaccine. I have served on numerous vaccine advisory committees, including a WHO committee for the long-term safety assessment of dengue vaccines.

---

## Eder Gatti Fernandes

Médico infectologista, com mestrado e doutorado em Saúde Coletiva, atua na Divisão de Imunização do Centro de Vigilância Epidemiológica "Prof. Alexandre Vranjac" e no Instituto de Infectologia Emílio Ribas.

---

## Fabio Lievano

Dr. Lievano has extensive experience in medicine, clinical development, risk management, epidemiology, pharmacovigilance at several pharmaceutical companies. In addition, he worked as a public health expert at the World Health Organization (WHO) European Regional Office and he was a researcher at the Centers for Disease Control and Prevention (CDC) in Atlanta. Dr. Lievano is a physician from Colombia also trained in epidemiology at the prestigious Epidemiology Intelligence Service of the CDC. In the pharmaceutical industry as Vicepresident of Safety Science at ABBVIE he manages a large team of scientists (MDs, PhDs, statisticians) in several therapeutic areas mainly

Immunology, Oncology and Vaccines. He has authored several papers and abstracts in many medical journals and major scientific conferences. Finally, in connection with his CDC work he received several awards for distinguished service by the United States Secretary of Health and Human Services. In his current job as Vicepresident of Safety Sciences, he manages several teams of scientists including physicians in several therapeutic areas, PhDs, statisticians, among others. Finally, he has authored several papers and abstracts in major medical journals and scientific meetings worldwide. In connection with the CDC work he received several scientific awards.

---

## Helaine Carneiro Capucho

Pharmacovigilance Manager at Brazilian Health Regulatory Agency – Anvisa, she is professor and researcher at University of Brasilia (UnB) for the Department of Pharmacy of the Faculty of Health. She is the current president of the Latin American Chapter of the International Pharmacovigilance Society - ISoP. Pharmacist at the Federal University of Ouro Preto, is a specialist, master and PhD. at the University of São Paulo - Campus Ribeirão Preto. Working for more than 15 years with pharmacovigilance, she was responsible for implementing Patient Safety and pharmacovigilance programs in 40 Brazilian federal teaching hospitals. Her publications are focused on hospital pharmacy, pharmacovigilance and patient safety.

---

## José Cassio de Moraes

Medico epidemiologista, Professor Titular Departamento de Saúde Coletiva, Faculdade de Ciências Médicas Santa Casa de São Paulo, presidente da Comissão Permanente de assessoria em imunização da SES SP, comissão técnica em imunização da Secretaria de Vigilância em Saúde, consultoria para Organização Pan-americana de Saúde, ex Diretor do Centro de Vigilância Epidemiológica da SES SP.

---

## Katharina Hartmann, PharmD

After training in drug formulation, drug information, and clinical pharmacology and pharmacoepidemiology she joined 1989 the national spontaneous reporting scheme Swiss Drug Monitoring Center as Medical Deputy Director.

From 2001-2013 she served as Global PV Head and QPPV for Crucell (former Berna Biotech) and since 2011 for J&J / Janssen Vaccines. She established Crucell's global pre- and post-authorization PV system, implemented a new validated PV software system, and after acquisition by J&J integrated Crucell's Vaccine PV into J&J's Global PV.

From 2013 - 2018 she served as Global Head Vaccine PV for Takeda's new Vaccine Business Unit where she was responsible for the set-up, implementation, and establishment of Takeda's Global Vaccine PV.

Since 2019 she is supporting DCVMN as an Independent Consultant for Pharmacovigilance / Pharmacoepidemiology and since October 2020 she supports CEPI as Co-Lead of the COVAX Vaccine Safety Working Group.

She has for many years a Senior Lecturer in PV and Pharmacoepidemiology at Master level at the Swiss Federal Institute of Technology (ETH), and was an appointed member of the CIOMS Vaccine Safety Working Group.

## Morgan A. Marks

Morgan Marks is a Senior Principal Scientist in the Department of Pharmacoepidemiology, Center for Observational and Real-World Evidence (CORE) at Merck and Co. Inc.. He received his PhD in Molecular Epidemiology in 2009 from the Johns Hopkins Bloomberg School of Public Health and was a post-doctoral fellow at Johns Hopkins and the US National Cancer Institute from 2009-2013. Morgan's prior research has focused on describing the clinical manifestations and immunologic mechanisms underlying infectious diseases such as human papillomavirus, Chagas, dengue, as well as other neglected tropical diseases in populations in North and South America, and Asia. After joining Merck in 2013, he served as the lead epidemiologist on a variety of pre-licensure and in-line vaccines produced by Merck. He currently supports Merck's dengue vaccine development program and leads a post-approval safety study of Gardasil® in males as well as a long-term post-approval effectiveness study of Zostavax®.

---

## Dr. Renato Kfoury

Dr. Kfoury is a Member of the Permanent Advisory Board on Immunization Practices for the Ministry of Health in Brazil and also Medical Director of Santa Joana Immunization Center, a large immunization clinic in São Paulo – a position he has held since their foundation in 1997.

He is currently the Director of Brazilian Society Immunization, and is the chairman of the Department of Immunisation for the Brazilian Society of Pediatrics and also is a member of the Committee of Pediatric Infectious Diseases of São Paulo Pediatric Society.

He is also a member of Sociedade Latino americana de Infectologia Pediátrica, and member the European Society of Pediatric Infectious Diseases.

He has been working with immunization for more than 25 years with long experience in public and private institutes.

Dr. Kfoury has spoken to a number of national and international conferences and workshops, and has contributed with papers and book chapters, on the subject of immunization.

---

## Sandra Maria Deotti Carvalho

### Formação Acadêmica

- Graduação em Medicina – Faculdade de Medicina da Universidade Federal de Juiz de Fora – MG, 1979.
- Mestrado em Saúde Pública: Escola Nacional de Saúde Pública de Havana, Cuba
- Médica Brasileira e Sociedade Brasileira de Pediatria em 29 de Maio de 1994.
- Médica concursada do Ministério da Saúde

### Atividade profissional atual

- Coordenação Geral do Programa Nacional de Imunização da Secretaria de Vigilância em Saúde/Ministério da Saúde – consultora técnica pela Organização Panamericana da Saúde - OPAS
- 

## Victor Bertollo

Victor Bertollo é médico com especialização em infectologia e medicina tropical pela Universidade de São Paulo, mestre em medicina tropical e saúde internacional pela London School of Hygiene and Tropical Medicine, com ênfase em epidemiologia e vacinologia. É consultor da Coordenação Geral do Programa Nacional de Imunizações, atuando dentro da farmacovigilância, acompanhamento da realização de estudos pós-implantação (fase 4) bem como auxiliando na elaboração de políticas de vacinação.